Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Add-on to metformin with or without SGLT2 inhibitor SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily
Drug design challenges Several issues must be addressed concerning the development of an efficacious drug to treat AD: (1) the drug must penetrate the BBB to influence damaged neurons in memory-associated brain structures
Comparing the efficacy of Myjet-assisted tranexamic acid and vitamin C in treating melasma: a split-face controlled trial
The study is foundational to Russian clinical use of Semax
US$ 22.82
US$ 24.54
US$ 20.47
US$ 27.37
US$ 23.13
US$ 24.09
US$ 24.40
